GTC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE ADVANCED SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Genes to Cells (2008) 13, 471-481. doi:10.1111/j.1365-2443.2008.01180.x
© 2008 Blackwell Publishing or its licensors

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nomme, J.
Right arrow Articles by Takahashi, M.
PubMed
Right arrow Articles by Nomme, J.
Right arrow Articles by Takahashi, M.

Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein

Julian Nomme1, Yoshimasa Takizawa2, Susan F. Martinez1, Axelle Renodon-Cornière1, Fabrice Fleury1, Pierre Weigel1, Ken-ichi Yamamoto3, Hitoshi Kurumizaka2 and Masayuki Takahashi1,*

1 UMR 6204, Centre National de la Recherche Scientifique, Université de Nantes, 44322 Nantes cedex 3, France
2 Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
3 Research Institute of Cancer, Kanazawa University, 13-1 Takara-machi, Kanazawa-shi 920-0934, Japan

Human Rad51 is a key element of recombinational DNA repair and is related to the resistance of cancer cells to chemo- and radiotherapies. The protein is thus a potential target of anti-cancer treatment. The crystallographic analysis shows that the BRC-motif of the BRCA2 tumor suppressor is in contact with the subunit–subunit interface of Rad51 and could thus prevent filament formation of Rad51. However, biochemical analysis indicates that a BRC-motif peptide of 69 amino acids preferentially binds to the N-terminal part of Rad51. We show experimentally that a short peptide of 28 amino acids derived from the BRC4 motif binds to the subunit–subunit interface and dissociates its filament, both in the presence and absence of DNA, certainly by binding to dissociated monomers. The inhibition is efficient and specific for Rad51: the peptide does not even interact with Rad51 homologs or prevent their interaction with DNA. Neither the N-terminal nor the C-terminal half of the peptide interacts with human Rad51, indicating that both parts are involved in the interaction, as expected from the crystal structure. These results suggest the possibility of developing inhibitors of human Rad51 based on this peptide.


Communicated by: Moshe Yaniv

* Correspondence: Email: masayuki.takahashi{at}univ-nantes.fr







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE ADVANCED SEARCH TABLE OF CONTENTS
Copyright © 2008 by Wiley-Blackwell Publishing.